This has clear implications for the prognosis of patients carrying TET2 mutations where AHN, often present in patients with aggressive forms of systemic mastocytosis, could progress from crosstalk between TET2/KITD816V mutated mast cells and myeloid progenitor cells in the BM. The gene discussed is TET2; the disease is systemic mastocytosis.